Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Summary

Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The companys products include Hetlioz, a melatonin receptor agonist for the treatment of non-24-hour sleep-wake disorder; and Fanapt, an atypical antipsychotic for the treatment of schizophrenia in adults. Its pipeline portfolio includes Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist for pruritus in atopic dermatitis; VQW-765 (formerly AQW-051), an alpha-7 nicotinic acetylcholine receptor for CNS disorders; and VTR-297 (formerly Trichostatin A) for oncology indications. Vanda Pharmaceuticals is headquartered in Washington DC, the US.

Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.


List of Tables 4
List of Figures 4
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 10
Licensing Agreements 10
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Equity Offering 13
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Acquisition 21
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc - Key Competitors 22
Vanda Pharmaceuticals Inc - Key Employees 23
Vanda Pharmaceuticals Inc - Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
May 02, 2018: Vanda Pharmaceuticals Reports First Quarter 2018 Financial Results 25
Feb 14, 2018: Vanda Pharmaceuticals Reports Fourth Quarter 2017 Financial Results 26
Jan 07, 2018: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2017 Revenue Results and 2018 Guidance 27
Nov 07, 2017: Vanda Pharmaceuticals Reports Third Quarter 2017 Financial Results 28
Aug 02, 2017: Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results 29
May 02, 2017: Vanda Pharmaceuticals Reports First Quarter 2017 Financial Results 30
Feb 15, 2017: Vanda Pharmaceuticals Reports Fourth Quarter 2016 and Full Year 2016 Financial Results 31
Jan 09, 2017: Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2016 Revenue Results and 2017 Financial Guidance 32
Appendix 33
Methodology 33
About GlobalData 33
Contact Us 33
Disclaimer 33

List Of Tables

List of Tables
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vanda Pharma Enters into Licensing Agreement with UC San Francisco 10
Novartis Pharma Enters into Licensing Agreement with Vanda Pharma for AQW-051 11
Vanda Pharma Enters Into Licensing Agreement With Eli Lilly For VLY-686 12
Vanda Pharma Prices Public Offering of Shares for USD93.5 Million 13
Vanda Pharma Raises USD25 Million in Private Placement of Common Stock 15
Vanda Pharma Raises USD66.7 Million in Public Offering of Shares 17
Vanda Pharma Completes Public Offering Of Shares For US$52 Million 19
Vanda Pharma May Sell Itself 21
Vanda Pharmaceuticals Inc, Key Competitors 22
Vanda Pharmaceuticals Inc, Key Employees 23
Vanda Pharmaceuticals Inc, Subsidiaries 24

List Of Figures

List of Figures
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vanda Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Vanda Pharmaceuticals Inc (VNDA) - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Vanda Pharmaceuticals Inc (Vanda Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializesnovel therapies for the treatment of central nervous system disorders. The companys products include Hetlioz, a melatonin

USD 250 View Report

Vanda Pharmaceuticals Inc Company Profile - Business Operations, Strategies, SWOT Analysis and Financial Report

Vanda Pharmaceuticals Inc Company Profile is a detailed strategic and analytical report on Vanda Pharmaceuticals Inc. The 2018 version of the report offers detailed insights into the companys strategies, developments,

USD 200 View Report

Constellation Pharmaceuticals Inc (CNST) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Constellation Pharmaceuticals Inc (Constellation) is a clinical biopharmaceutical company that focuses to develop novel therapeutics for the treatment of serious unmet medical needs in patients with cancers associated with abnormal

USD 250 View Report

Cannabics Pharmaceuticals Inc (CNBX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Cannabics Pharmaceuticals Inc (Cannabics Pharmaceuticals), formerly Thrust Energy Corp, is a drug development company that develops cannabinoid-based therapies for cancer. The company develops High Content Screening (HCS) Platform, an automated

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available